Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-day vs 7-day Azacitidine in Lower-risk MDS
NCT01652781Phase 2Unknown
- Sponsor
- Seoul St. Mary's Hospital
- Start
- Mar 2012
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of azacitidine in myelodysplastic syndrome (MDS) (2 arms), sponsored by Seoul St. Mary's Hospital. Primary endpoint: Overall Response Rate. Status: unknown.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01652781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01652781.